The phenomenon of a genetic aberration that may be associated with a worse prognosis if no effective systemic treatments are administered is reminiscent of the clinical significance of BRAFV600 mutations in MM; although BRAFV600 mutations are associated with worse outcomes, treatment with a BRAF inhibitor may improve outcome to the degree that is similar to that of patients without BRAFV600 mutation [16]. This evidence concerns the gene BRAF and Miyoshi myopathy.